[go: up one dir, main page]

PA8527301A1 - 7-OXO-PYRIDOPIRIMIDINAS - Google Patents

7-OXO-PYRIDOPIRIMIDINAS

Info

Publication number
PA8527301A1
PA8527301A1 PA20018527301A PA8527301A PA8527301A1 PA 8527301 A1 PA8527301 A1 PA 8527301A1 PA 20018527301 A PA20018527301 A PA 20018527301A PA 8527301 A PA8527301 A PA 8527301A PA 8527301 A1 PA8527301 A1 PA 8527301A1
Authority
PA
Panama
Prior art keywords
disease
pyridopirimidinas
oxo
caused
syrdrome
Prior art date
Application number
PA20018527301A
Other languages
Spanish (es)
Inventor
Jian Jeffrey Chen
James Patrick Dunn
Julie Anne Lim
David Michael Goldstein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8527301A1 publication Critical patent/PA8527301A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA: EN LA QUE R1, R2, R3 Y AR1 TIENEN LOS SIGNIFICADOS DEFINIDOS EN LA INVENCION, Y A METODOS DE OBTENCION Y A SU UTILIZACION PARA EL TRATAMIENTO DE TRASTORNOS CAUSADOS POR P38, P. EJ. EL METODO DE LA REIVINDICACION 26 O 27, EN EL QUE DICHO TRASTORNO CAUSADO POR P38 SE SELECCIONA ENTRE LA ARTRITIS, LA ENFERMEDAD DE CROHN, LA ENFERMEDAD DE ALZHEIMER, EL SINDROME DE INTESTINO IRRITABLE, EL SINDROME DE LA DEFICIENCIA RESPIRATORIA ADULTA Y LA ENFERMEDAD PUILMONAR OBSTRUCTIVA CRONICA.THE PRESENT INVENTION CONCERNS COMPOUNDS OF THE FORMULA: IN WHICH R1, R2, R3 AND AR1 HAVE THE MEANINGS DEFINED IN THE INVENTION, AND METHODS OF OBTAINING AND THEIR USE FOR THE TREATMENT OF CAUSES CAUSED BY P38, P. EX. THE METHOD OF THE REIVINDICATION 26 OR 27, IN WHICH SUCH DISORDER CAUSED BY P38 IS SELECTED BETWEEN ARTHRITIS, CROHN'S DISEASE, ALZHEIMER'S DISEASE, IRRITABLE INTESTINE SYNDROME, SYRDROME OF RESPIRATORY ADULMULARITY CHRONIC OBSTRUCTIVE.

PA20018527301A 2000-08-31 2001-08-28 7-OXO-PYRIDOPIRIMIDINAS PA8527301A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22958400P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
PA8527301A1 true PA8527301A1 (en) 2002-07-30

Family

ID=22861859

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018527301A PA8527301A1 (en) 2000-08-31 2001-08-28 7-OXO-PYRIDOPIRIMIDINAS

Country Status (15)

Country Link
EP (1) EP1315726A1 (en)
JP (1) JP4141830B2 (en)
KR (1) KR100571339B1 (en)
CN (1) CN1275964C (en)
AR (1) AR033681A1 (en)
AU (2) AU9378401A (en)
BR (1) BR0113628A (en)
CA (1) CA2420286A1 (en)
GT (1) GT200100191A (en)
MX (1) MXPA03001821A (en)
PA (1) PA8527301A1 (en)
PE (1) PE20020406A1 (en)
UY (1) UY26918A1 (en)
WO (1) WO2002018380A1 (en)
ZA (1) ZA200301079B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518276B2 (en) 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
BR0113590A (en) * 2000-08-31 2003-07-22 Hoffmann La Roche 7-oxopyridopyrimidines
JP2006503802A (en) * 2002-04-03 2006-02-02 エフ．ホフマン−ラ　ロシュ　アーゲー Imidazo condensation compounds
WO2003088972A1 (en) * 2002-04-19 2003-10-30 Smithkline Beecham Corporation Novel compounds
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
UY27939A1 (en) 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
EP1565475B1 (en) 2002-11-18 2009-04-08 F. Hoffmann-La Roche Ag Diazinopyrimidines and their use as protein kinase inhibitors
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
KR20050111636A (en) 2003-04-10 2005-11-25 에프. 호프만-라 로슈 아게 Pyrimido compounds
US20070020234A1 (en) * 2003-07-07 2007-01-25 Vande Woude George F Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
EP1685131B1 (en) * 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
WO2005105097A2 (en) * 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20090131430A1 (en) * 2004-11-23 2009-05-21 Palle Venkata P Pyrido'2,3-dipyrimidines as anti-inflammatory agents
US20090036472A1 (en) * 2005-02-02 2009-02-05 Palle Venkata P Azabicyclo derivatives as anti-inflammatory agents
WO2007036791A1 (en) * 2005-09-28 2007-04-05 Ranbaxy Laboratories Limited Pyrido-pyridimidine derivatives useful as antiinflammatory agents
ATE439361T1 (en) 2006-01-31 2009-08-15 Hoffmann La Roche 7H-PYRIDOÄ3,4-DÜPYRIMIDINE-8-ONE, THEIR PREPARATION AND THEIR USE AS PROTEIN KINASE INHIBITORS
KR100661523B1 (en) * 2006-06-09 2006-12-26 주식회사 청용산기 Improved torsion correction device mounted on carton manufacturing equipment
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JP2010509265A (en) 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー Substituted 6-phenyl-pyrido [2,3-D] pyrimidin-7-one derivatives as kinase inhibitors and methods of use thereof
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
KR101106162B1 (en) * 2010-04-20 2012-01-20 주식회사 청용산기 Unloading guide support unit in stitching device for packing box manufacturing equipment
JP6101341B2 (en) * 2012-03-22 2017-03-22 オスコテック, インコーポレーテッドOscotec, Inc. Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
AR095464A1 (en) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc HETEROARILO COMPOUNDS AND USES OF THE SAME
WO2016037255A2 (en) 2014-09-12 2016-03-17 Biolab Sanus Farmacêutica Ltda. New pyridopyrimidines derivatives compounds
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (en) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
TWI831829B (en) 2018-09-12 2024-02-11 美商建南德克公司 Phenoxy-pyridyl-pyrimidine compounds and methods of use
US12077534B2 (en) 2018-12-27 2024-09-03 Les Laboratoires Servier Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer
JP7539892B2 (en) 2019-01-03 2024-08-26 ジェネンテック， インコーポレイテッド Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol-requiring enzyme I (IREI alpha) for the treatment of cancer diseases - Patents.com
US20220251081A1 (en) * 2019-05-31 2022-08-11 Les Laboratoires Servier Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
WO2022052924A1 (en) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 Preparation method for class of nitrogen-containing fused ring compounds and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2146782T3 (en) * 1994-11-14 2000-08-16 Warner Lambert Co 6-ARYL-PIRIDO (2,3-D) PIRIMIDINAS AND NAFTIRIDINAS FOR THE INHIBITION OF THE CELL PROLIFERATION INDUCED BY THE PROTEIN TIROSINA QUINASA.
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
EE200000706A (en) * 1998-05-26 2002-06-17 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cell proliferation

Also Published As

Publication number Publication date
AR033681A1 (en) 2004-01-07
PE20020406A1 (en) 2002-05-17
AU9378401A (en) 2002-03-13
CA2420286A1 (en) 2002-03-07
KR100571339B1 (en) 2006-04-17
AU2001293784B2 (en) 2007-08-30
CN1275964C (en) 2006-09-20
GT200100191A (en) 2002-05-16
JP4141830B2 (en) 2008-08-27
EP1315726A1 (en) 2003-06-04
WO2002018380A1 (en) 2002-03-07
MXPA03001821A (en) 2003-06-04
CN1451005A (en) 2003-10-22
KR20030022422A (en) 2003-03-15
ZA200301079B (en) 2004-05-07
UY26918A1 (en) 2002-02-28
JP2004507541A (en) 2004-03-11
BR0113628A (en) 2003-07-01

Similar Documents

Publication Publication Date Title
PA8527301A1 (en) 7-OXO-PYRIDOPIRIMIDINAS
CR9465A (en) PHARMACOCINETICALLY IMPROVED COMPOUNDS
DK1346041T3 (en) Therapeutic agents and methods for their use in the treatment of an amyloidogenic disease
CY1111246T1 (en) PREVENTION AND TREATMENT OF INFLAMMATORY AND / OR IMMUNIATED BONE LOSS
BR0307998A (en) Substituted hydroxyethylamines
UY29919A1 (en) SUBSTITUTED DERIVATIVES OF 3,4-DIHYDROISOQUINOLIN-1-AMINO-TRIFLUOROACETATE, ITS PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS
ECSP077401A (en) MEDICATIONS CONTAINING CARBON COMPOUNDS AND THEIR USE
CY1108714T1 (en) CGRP RACE COMPETITORS
BR0011448A (en) Amide Substituted Imidazoquinolines
UY28376A1 (en) THERAPEUTIC AGENTS
EA200201247A1 (en) CONNECTIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
BRPI0212733B8 (en) pharmaceutical composition comprising serotonin reuptake inhibitor compound, and use thereof
BRPI0607017B8 (en) pharmaceutical composition comprising memantine and donezepil, and their use for the treatment of snc-related conditions
BR0116034A (en) Substituted imidazopyridines
GB0108592D0 (en) Therapeutic agents
CY1107956T1 (en) USE OF 2-AMINOTETRALINE SUBSTITUTES FOR PREVENTIVE TREATMENT OF PARKINS DISEASE
SE0301446D0 (en) New Compounds
CY1110537T1 (en) UNIONS AND METHODS FOR THE DISEASE EDUCATION
CY1108808T1 (en) MOTORCYCLE UNITS
BR0316723A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
UY28377A1 (en) THERAPEUTIC AGENTS
BR0211830A (en) Azithromycin single dose
DE60011560D1 (en) Salmonella vaccine that does not induce antibody to Flagellin or Flagella
AR043253A1 (en) 4 - [(2,4-DICLORO-5-METOXIFENIL) AMINO] -6- CARBONITRILE ALCOXI-3-CHINOLINE FOR THE TREATMENT OF ISCHEMICAL INJURIES
PL372769A1 (en) Cyanoguanidine prodrugs